Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity

American Journal of Obstetrics and Gynecology

Volumn 198, Issue 4, 2008, Pages 370.e1-370.e7

  Helms, Donna J ^a   Mosure, Debra J ^a   Secor, W Evan ^b   Workowski, Kimberly A ^a,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Centers for Disease Control and Prevention   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

desensitization; hypersensitivity; metronidazole; tinidazole; trichomonas

Indexed keywords

ACETARSOL; CLOTRIMAZOLE; FURAZOLIDONE; METRONIDAZOLE; PAROMOMYCIN; POVIDONE IODINE; TINIDAZOLE;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; DESENSITIZATION; ERADICATION THERAPY; ERYTHEMA; FACE EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PRURITUS; TREATMENT OUTCOME; TREATMENT PLANNING; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; URTICARIA;

EID: 41349090082     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.10.795     Document Type: Article

References (29)

1. Weinstock H., Berman S., and Cates Jr. W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 36 (2004) 6-10
2. Sutton M.Y., Sternberg M.R., Koumans E., McQuillan G., Berman S., and Markowitz L. Prevalence of Trichomonas vaginalis in the United States, 2001-2002. [abstract 213]. Program and abstracts of the 2006 National STD Prevention Conference (Jacksonville, FL) (2006). http://cdc.confex.com/cdc/std2006/techprogram/P11180.HTM Available at: http://cdc.confex.com/cdc/std2006/techprogram/P11180.HTM.Accessed Dec. 11
3. Krieger J.N., and Anagonou S. Trichomonas vaginalis and trichomoniasis. In: Holmes K.K., Sparling P.F., Mardh P.A., et al. (Eds). Sexually transmitted diseases. 3rd ed. (1997), McGraw-Hill, New York 587-604
4. Heine P., and McGregor J.A. Trichomonas vaginalis: a reemerging pathogen. Clin Obstet Gynecol 36 (1993) 137-144
5. Cates Jr. W. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis 26 (1999) S2-S7
6. Laga M., Alary M., Nzila N., et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 344 (1994) 246-248
7. McClelland R.S., Sangaré L., Hassan W.M., et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 195 (2007) 698-702
8. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR Morb Mortal Wkly Rep 55 RR-11 (2006) 52-54
9. Nanda N., Michel R.G., Kurdgelashvili G., and Wendel K.A. Trichomoniasis and its treatment. Expert Rev Anti Infect Ther 4 (2006) 125-135
10. Mishra D., Mobashir M., and Zaheer M.S. Fixed drug eruption and cross-reactivity between tinidazole and metronidazole. Int J Dermatol 29 (1990) 740
11. Prieto A., De B.M., Infante S., Torres A., Rubio M., and Olalde S. Recurrent fixed drug eruption due to metronidazole elicited by patch test with tinidazole. Contact Dermatitis 53 (2005) 169-170
12. van der Pol B. Trichomonas vaginalis infection: the most prevalent nonviral sexually transmitted infection receives the least public health attention. Clin Infect Dis 44 (2007) 23-25
13. Pearlman M.D., Yashar C., Ernst S., and Solomon W. An incremental dosing protocol for women with severe vaginal trichomoniasis and adverse reaction to metronidazole. Am J Obstet Gynecol 174 (1996) 934-936
14. Kurohara M.L., Kwong F.K., Lebherz T.B., and Klaustermeyer W.B. Metronidazole hypersensitivity and oral desensitization. J Allergy Clin Immunol 88 (1991) 279-280
15. Yu H., and Tak-Yin M. The efficacy of povidone-iodine pessaries in a short, low-dose treatment regime on candidal, trichomonal and non-specific vaginitis. Postgrad Med J 69 (1993) S58-S61
16. Porapakkham S. Metronidazole treatment of vaginal trichomoniasis. II. Oral vs. vaginal therapy. Obstet Gynecol 29 (1967) 213-216
17. Coelho D.D. Metronidazole resistant trichomoniasis successfully treated with paromomycin. Genitourin Med 73 (1997) 397-398
18. Poppe W.A. Nitroimidazole-resistant vaginal trichomoniasis treated with paromomycin. Eur J Obstet Gynecol Reprod Biol 96 (2001) 119-120
19. Legal H.P. The treatment of trichomonas and candida vaginitis with clotrimazole vaginal tablets. Postgrad Med J 50 Suppl 1 (1974) 81-83
20. Chen M.Y. Acetarsol pessaries in the treatment of metronidazole resistant Trichomonas vaginalis. Int J STD AIDS 10 (1999) 277-280
21. Waters L.J., Dave S.S., Deayton J.R., and French P.D. Recalcitrant Trichomonas vaginalis infection-a case series. Int J STD AIDS 16 (2005) 505-509
22. Nyirjesy P., Sobel J.D., Weitz M.V., Leaman D.J., and Gelone S.P. Difficult-to-treat trichomoniasis: results with paromomycin cream. Clin Infect Dis 26 (1998) 986-988
23. duBouchet L., Spence M.R., Rein M.F., Danzig M.R., and McCormack W.M. Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. Sex Transm Dis 24 (1997) 156-160
24. Mammen-Tobin A., and Wilson J.D. Management of metronidazole-resistant Trichomonas vaginalis-a new approach. Int J STD AIDS 16 (2005) 488-490
25. Stern I.J., Hollifield R.D., Wilk S., and Buzard J.A. The anti-monoamine oxidase effects of furazolidone. J Pharmacol Exp Ther 156 (1967) 492-499
26. Narcisi E.M., and Secor W.E. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Antimicrob Agents Chemother 40 (1996) 1121-1125
27. Schwartz J. Tricofuron therapy of Trichomonas vaginitis. Obstet Gynecol 7 (1956) 312-314
28. Walker P.P. Arsenical pessaries in the treatment of metronidazole-resistant Trichomonas vaginalis. Int J STD AIDS 8 (1997) 473
29. Swygard H., Seña A.C., Hobbs M.M., and Cohen M.S. Trichomiasis: clinical manifestations, diagnosis and management. Sex Transm Infect 80 (2004) 91-95